Volume 5.42 | Oct 24

Mammary Cell News 5.42 October 24, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
A Novel Model of Dormancy for Bone Metastatic Breast Cancer Cells
Scientists established novel experimental systems that model the bone microenvironment of the breast cancer metastatic niche. These systems are based on 3D co-cultures of breast cancer cells with cell types predominant in bone marrow. [Cancer Res] Abstract
Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
PUBLICATIONS (Ranked by impact factor of the journal)

High-Throughput Screens Identify MicroRNAs Essential for HER2 Positive Breast Cancer Cell Growth
Researchers characterized the role of microRNAs (miRNAs) in regulating the human epidermal growth factor receptor 2 (HER2)-pathway in breast cancer. They performed miRNA gain-of-function assays by screening two HER2 amplified cell lines with a miRNA mimic library consisting of 810 human miRNAs. [Mol Oncol] Abstract

A siRNA Screen Identifies RAD21, EIF3H, CHRAC1 and TANC2 as Driver Genes within the 8q23, 8q24.3 and 17q23 Amplicons in Breast Cancer with Effects on Cell Growth, Survival and Transformation
Investigators performed a siRNA screening, in three breast cancer cell lines, for 101 candidate driver genes overexpressed in amplified breast tumors and belonging to eight amplicons on chromosomes 8q and 17q, investigating their role in cell survival/proliferation. [Carcinogenesis] Abstract

Targeted Therapy against EGFR and VEGFR Using ZD6474 Enhances the Therapeutic Potential of UV-B Phototherapy in Breast Cancer Cells
Breast cancer cells were exposed to UV-B and ZD6474 and the cell viability, apoptosis, invasion and motility studies were conducted for the combinatorial effect. [Mol Cancer] Abstract | Full Article

COUP-TFII inhibits NFkappaB Activation in Endocrine-Resistant Breast Cancer Cells
Scientists aimed to determine if COUP-TFII modulates NFkappa B (NFκB) activity. Endocrine-resistant LCC9 cells with low endogenous COUP-TFII displayed ~five-fold higher basal NFκB activity than parental endocrine-sensitive MCF-7 breast cancer cells. [Mol Cell Endocrinol] Abstract

Generation of Breast Cancer Stem Cells by Steroid Hormones in Irradiated Human Mammary Cell Lines
To assess whether the modulation of radiation-induced breast cancer risk by steroid hormones could involve cancer stem cells (CSCs), researchers measured by flow cytometry the proportion of CSCs in irradiated breast cancer cell lines after progesterone and estrogen treatment. [PLoS One] Full Article

Mechanistic Insights into the Cytotoxicity and Genotoxicity Induced by Glycidamide in Human Mammary Cells
The authors addressed the characterization and modulation of cytotoxicity, generation of reactive oxygen species, formation of micronuclei and quantification of specific glycidamide (GA)-DNA adducts in human MCF10A epithelial cells exposed to GA. [Mutagenesis] Abstract

Establishment and Characterization of Seven Human Breast Cancer Cell Lines Including Two Triple-Negative Cell Lines
The authors report the characteristics of seven cell lines designated, SNU-306, SNU-334, SNU-1528, SNU-1553, SNU-1581, SNU-1958 and SNU-2372, which were established from three primary carcinomas, two pleural effusion, one pericardial effusion and one ascitic fluid samples obtained from seven Korean breast carcinoma patients. [Int J Oncol] Abstract

Tranilast Enhances the Anti-Tumor Effects of Tamoxifen on Human Breast Cancer Cells In Vitro
Investigators evaluated the effect of tamoxifen when used in combination with tranilast on human breast cancer cells. Two MCF-7 and MDA-MB-231 human breast cancer cell lines were treated with tamoxifen and/or tranilast. [J Biomed Sci] Abstract | Full Article


Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
In a recent Phase III trial in patients with metastatic breast cancer who previously received trastuzumab and a taxane, trastuzumab emtansine resulted in improved progression-free and overall survival compared to capecitabine and lapatinib. [Clin Cancer Res] Abstract

Use Aldefluor to Detect Breast Cancer Stem Cells - Click here to learn more
Clinical Application of High-Throughput Genomic Technologies for Treatment Selection in Breast Cancer
The authors provide an overview of the recent molecular insights in breast cancer, including potentially actionable somatic alterations, the technological platforms currently available in a clinical diagnostics setting to detect these alterations, and ongoing institutional or regional molecular screening programs in advanced breast cancer. [Breast Cancer Res] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
BROCA Sequencing Approach Evaluates All 24 Genes Implicated in Breast Cancer
Researchers found that over 25 percent of index patients with normal results from commercial testing of BRCA1 and BRCA2, but with families severely affected by breast cancer, could be resolved by sequencing all genes known to be involved in breast cancer. [Press release from EurekAlert! discussing research presented at the American Society of Human Genetics 2013 Meeting, Boston] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
Seattle Genetics Initiates Phase I Trial of ADC Candidate, SGN-LIV1A, for Patients with LIV-1-Positive Metastatic Breast Cancer
Seattle Genetics, Inc. announced the initiation of a Phase I clinical trial evaluating SGN-LIV1A for patients with LIV-1-positive metastatic breast cancer. SGN-LIV1A utilizes Seattle Genetics’ industry-leading antibody-drug conjugate (ADC) technology. The trial is designed to assess the safety and antitumor activity of SGN-LIV1A, an ADC targeted to LIV-1, a protein which is expressed in most subtypes of metastatic breast cancer. [Seattle Genetics, Inc.] Press Release

$1 Million Grant Could Help Put Brakes on Cancer
A Florida State University researcher’s study of the mechanics of cell division may one day help put the brakes on cancer. Yanchang Wang, associate professor in the College of Medicine’s Department of Biomedical Sciences, received a four-year, $1 million grant from the National Institutes of Health to continue his ongoing study. [Florida State University College of Medicine] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW European Society for Medical Oncology (ESMO) 2014 Congress
September 26-30, 2014
Madrid, Spain

Visit our events page to see a complete list of events in the mammary cell community.
PhD Position – Integrated Classification of Breast Cancers to Optimize Treatment Protocols (Radboud University Medical Center)

Postdoctoral Position – Breast Cancer Research (Karolinska Institute)

Postdoctoral Position – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology and Cancer Genomics (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology of Cancer (Gustave Roussy Cancer Institute)

PhD Position – Breast Cancer Bone Metastasis Formation (Claude Bernard University Lyon 1)

Postdoctoral Fellow – Breast Cancer Biology (Stephenson Cancer Center at the University of Oklahoma)

Research Assistant – Cellular Pathways Involved in Oncogenic Transformation of Breast Epithelial Cells (Mount Sinai School of Medicine)

Postdoctoral Fellow in Breast Cancer – (Bellvitge Biomedical Research Institute [IDIBELL])

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mammary Cell News: Archives | Events | Contact Us